CTOs on the Move

Bluebird Bio

www.bluebirdbio.com

 
At bluebird bio, we`re pioneering the uniquely promising world of gene therapy with a deep sense of purpose – to ensure lives are lived fully. To do it, we`re developing one-time gene therapies for severe genetic disease and cancer, while working to radically improve healthcare systems so gene therapy becomes truly accessible. We want to recode science, systems and the status quo – for life. We pride ourselves on having a unique culture that drives our success. A diverse flock of individual birds, we share common DNA that helps us build meaningful relationships with industry, patient & advocacy groups and ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Foxtag Enterprises

Foxtag Enterprises is a Rockledge, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acris Antibodies

Acris Antibodies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calysta Energy

Calysta, Inc. (www.calysta.com), Menlo Park, CA, is an innovator in industrial products for food and energy security. Calysta has two business units. Calysta Nutrition is developing and commercializing FeedKind™ protein, a natural, safe, non-GMO sustainable ingredient for fish feed and other applications. FeedKind™ protein is approved for sale in the European Union. Calysta Energy is developing high value industrial and chemical products with cost and performance advantages over current processes.

Prometheus Biosciences

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Immantics

Immatics Biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. Cancer immunotherapy is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate antigens specific to cancer cells. These antigens, also called Tumor-Associated Peptides (TUMAPs), are able to activate T cells which are responsible for identifying and destroying cancer cells. These well characterized TUMAPs can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), soluble T Cell Receptors (TCRs), Antibodies and Cancer Vaccines. The US based Immatics US, Inc., launched in Aug. 2015, is focused on the development of three ACT approaches for the treatment of tumors with high unmet medical needs: ACTolog™, ACTengine™, and ACTallo™ in close collaboration with leading scientists at the MD Anderson Cancer Center, who contribute their long-term ACT expertise. The first ACT products are expected to enter the clinic in 2016. Immatics signed a strategic cancer immunotherapy collaboration with Roche in November 2013 to research, develop and commercialize a number of new cancer peptide antigen-based immunotherapies. In addition, Immatics is engaged in the development of soluble T-cell receptor (sTCR) approaches as well as monoclonal antibodies (mABs) directed towards XPRESIDENT® targets. The latter will be pursued in a strategic alliance with MorphoSys. Immatics is further conducting the clinical development of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC; an EU-funded consortium) in collaboration with BioNTech. Immatics GmbH is based in Tübingen, Germany, with a headcount of approximately 90 people. Immatics US, Inc. is based in Houston, Texas, USA, and currently employs approximately 15 people.